Our pediatric genetics division regularly orders whole genome testing as part of E/M services, with

Our pediatric genetics division regularly orders whole genome testing as part of E/M services, with physicians obtaining patient consent. While our physicians receive credit in medical decision making (MDM) for ordering and reviewing these tests, they believe that performing whole genome testing-and the potential implications for patient management-should also be considered under the "Risk of Complications and/or Morbidity or Mortality" category. Specifically, they feel the risk associated with whole genome testing is comparable to prescription drug management. Can you clarify if this is something that can be counted under the risk category?

To view the Official AMA answer and 1000s more like this:

CPT® Knowledge Base is a compendium of real life coding questions asked by the coding community and answered by CPT® coding experts.

Over 2900 questions and authoritative answers from the CPT® professionals at the AMA. Get specific answers to challenging coding questions, and search the knowledge base of others' real world questions.

Access to this feature is available in the following products:

AMA's CPT® Advanced Coding Pack

Thank you for choosing Find-A-Code, please Sign In to remove ads.

MY NEWSLETTERS

FEES

FACILITY

RISK ADJUSTMENT

CPT Knowledgebase - Apr 29, 2026